| Literature DB >> 26671467 |
Kavita P Bhavan1,2, L Steven Brown2, Robert W Haley2,3.
Abstract
BACKGROUND: Outpatient parenteral antimicrobial therapy (OPAT) is accepted as safe and effective for medically stable patients to complete intravenous (IV) antibiotics in an outpatient setting. Since, however, uninsured patients in the United States generally cannot afford OPAT, safety-net hospitals are often burdened with long hospitalizations purely to infuse antibiotics, occupying beds that could be used for patients requiring more intensive services. OPAT is generally delivered in one of four settings: infusion centers, nursing homes, at home with skilled nursing assistance, or at home with self-administered therapy. The first three-termed healthcare-administered OPAT (H-OPAT)--are most commonly used in the United States by patients with insurance funding. The fourth--self-administered OPAT (S-OPAT)--is relatively uncommon, with the few published studies having been conducted in the United Kingdom. With multidisciplinary planning, we established an S-OPAT clinic in 2009 to shift care of selected uninsured patients safely to self-administration of their IV antibiotics at home. We undertook this study to determine whether the low-income mostly non-English-speaking patients in our S-OPAT program could administer their own IV antimicrobials at home with outcomes as good as, or better than, those receiving H-OPAT. METHODS ANDEntities:
Mesh:
Substances:
Year: 2015 PMID: 26671467 PMCID: PMC4686020 DOI: 10.1371/journal.pmed.1001922
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Baseline characteristics of the patients in the self-administered OPAT and healthcare-administered OPAT groups.
| Characteristic | Distribution of Baseline Characteristic by Outpatient Antimicrobial Management | ||
|---|---|---|---|
| S-OPAT ( | H-OPAT ( |
| |
|
| <0.001 | ||
| 16–24 | 36 (3.8) | 3 (1.3) | |
| 25–44 | 266 (28.2) | 33 (14.7) | |
| 45–64 | 513 (54.3) | 100 (44.6) | |
| ≥65 | 129 (13.7) | 88 (39.3) | |
|
| 0.87 | ||
| Male | 583 (61.8) | 137 (61.6) | |
| Female | 361 (38.2) | 87 (38.8) | |
|
| <0.001 | ||
| White non-Hispanic | 213 (22.6) | 73 (32.6) | |
| Hispanic | 461 (48.8) | 43 (19.2) | |
| Black non-Hispanic | 236 (25.0) | 100 (44.6) | |
| Other | 34 (3.6) | 8 (3.6) | |
|
| <0.001 | ||
| English only | 599 (63.5) | 197 (88.0) | |
| Spanish only | 322 (34.1) | 24 (10.7) | |
| Other language only | 23 (2.4) | 3 (1.3) | |
|
| <0.001 | ||
| Central city core | 900 (95.3) | 198 (88.4) | |
| Suburban | 19 (2.01) | 11 (4.9) | |
| Rural | 19 (2.01) | 15 (6.7) | |
| Missing data | 6 (0.6) | 0 (0.0) | |
|
| <0.001 | ||
| Medicare | 168 (17.8) | 129 (57.6) | |
| Medicaid | 140 (14.8) | 60 (26.8) | |
| Private insurance | 61 (6.5) | 15 (6.7) | |
| Charity | 314 (33.3) | 9 (4.0) | |
| Self-pay | 261 (27.6) | 11 (4.9) | |
|
| <0.001 | ||
| 2010 | 104 (11.0) | 108 (48.2) | |
| 2011 | 231 (24.5) | 43 (19.2) | |
| 2012 | 305 (32.3) | 42 (18.8) | |
| 2013 | 304 (32.2) | 31 (13.8) | |
|
| <0.001 | ||
| Underweight (<18.5) | 26(2.8) | 17 (7.6) | |
| Normal (18.5–24.9) | 210 (22.3) | 47 (21.0) | |
| Overweight (25.0–29.9) | 288 (30.5) | 31 (13.8) | |
| Obese (≥30.0) | 420 (44.5) | 129 (57.6) | |
|
| <0.001 | ||
| Bone and joint | 405 (42.9) | 53 (23.7) | |
| Bacteremia | 148 (15.7) | 33 (14.7) | |
| Skin and soft tissue | 96 (10.2) | 27 (12.1) | |
| Central nervous system | 42 (4.5) | 13 (5.8) | |
| Intra-abdominal | 35 (3.7) | 9 (4.0) | |
| Genitourinary | 122 (12.9) | 28 (12.5) | |
| Pulmonary/ENT | 32 (3.4) | 27 (12.1) | |
| Other type/site | 64 (6.8) | 35 (15.2) | |
|
| <0.001 | ||
| Yes | 195 (20.7) | 19 (8.5) | |
| No | 749 (79.3) | 205 (91.5) | |
|
| <0.001 | ||
| Yes | 92 (9.8) | 52 (23.2) | |
| No | 852 (90.3) | 172 (76.8) | |
Data are given as n (percent).
*The Medicare group includes patients ≥65 y of age as well as younger patients with certain disabilities. Charity healthcare funding refers to care received through Dallas County’s assistance program for residents, Parkland Health Plus, which is provided to uninsured patients earning ≤200% of the federal poverty level; uninsured patients earning >200% of the federal poverty level must pay for their healthcare (self-pay).
‡Fiscal years run from 1 October to 30 September. For H-OPAT, fiscal year 2010 also includes the 9 mo before the fiscal year (1 January 2009 to 30 September 2009).
ENT, ear/nose/throat.
Multivariable logistic regression model of propensity score for participation in the self-administered OPAT versus healthcare-administered OPAT program.
| Variable | aOR | 95% CI |
|
|---|---|---|---|
|
| <0.001 | ||
| Medicare | 1.00 (ref) | ||
| Medicaid | 1.09 | 0.64–1.84 | 0.76 |
| Private insurance | 1.04 | 0.48–2.27 | 0.93 |
| Charity | 9.02 | 4.08–19.96 | <0.001 |
| Self-pay | 11.07 | 5.15–23.81 | <0.001 |
|
| <0.001 | ||
| Pulmonary/ENT | 1.00 (ref) | ||
| Bone and joint | 9.29 | 3.93–21.96 | <0.001 |
| Bacteremia | 7.51 | 2.92–19.32 | <0.001 |
| Skin and soft tissue | 3.78 | 1.43–10.03 | 0.008 |
| Central nervous system | 2.80 | 0.91–8.65 | 0.07 |
| Intra-abdominal | 3.67 | 1.04–12.99 | 0.04 |
| Genitourinary | 4.00 | 1.52–10.52 | 0.005 |
| Other type/site | 3.04 | 1.16–8.00 | 0.024 |
|
| 0.63 | 0.54–0.74 | <0.001 |
|
| <0.001 | ||
| Suburban or rural | 1.00 (ref) | ||
| Central city core | 6.06 | 2.92–12.57 | <0.001 |
|
| <0.001 | ||
| English | 1.00 (ref) | ||
| Spanish only | 3.12 | 1.71–5.69 | <0.001 |
| Other language only | 3.77 | 0.72–19.86 | 0.12 |
|
| <0.001 | ||
| Underweight (<18.5) | 1.00 (ref) | ||
| Normal (18.5–24.9) | 1.12 | 0.44–2.82 | 0.81 |
| Overweight (25.0–29.9) | 3.15 | 1.23–8.10 | 0.017 |
| Obese (≥30.0) | 1.02 | 0.43–2.42 | 0.96 |
|
| <0.001 | ||
| 2010 | 0.07 | 0.04–0.13 | <0.001 |
| 2011 | 0.51 | 0.28–0.93 | 0.03 |
| 2012 | 0.59 | 0.33–1.08 | 0.09 |
| 2013 | 1.00 (ref) | ||
|
| <0.001 | ||
| No | 1.00 (ref) | ||
| Yes | 3.65 | 1.87–7.11 | <0.001 |
|
| <0.001 | ||
| No | 1.00 (ref) | ||
| Yes | 0.35 | 0.20–0.62 | <0.001 |
The model’s area under the receiver operating characteristic curve was 0.91. Patients’ predicted probability of S- OPAT participation from the model is the propensity score used to control for selection bias in later outcome modeling.
*The p-values for the main category terms (e.g., health funding source) are from the type 3 analysis of the main effects of the nine categorical variables, and the p-values for the individual category terms test the difference between each category (e.g., Medicaid) and its referent category (indicated by aOR = 1.00; e.g., Medicare), all based on a sample size of 1,168 patients.
‡Fiscal years run from 1 October to 30 September. For H-OPAT, fiscal year 2010 also includes the 9 mo before the fiscal year (1 January 2009 to 30 September 2009).
aOR, adjusted odds ratio; ENT, ear/nose/throat; ref, referent category.
Fig 1Summary of patient selection.
aPatients who were homeless, had a history of IV drug abuse, or were medically unstable. bThe eligibility criteria for inclusion in the S-OPAT group are given in S2 Fig.
Multivariable proportional hazards regression models of 30-d readmission.
| Variable | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| aHR | 95% CI |
| aHR | 95% CI |
| |
|
| 0.002 | 0.003 | ||||
| H-OPAT | 1.00 (ref) | 1.00 (ref) | ||||
| S-OPAT | 0.59 | 0.42–0.82 | 0.002 | 0.53 | 0.35–0.81 | 0.003 |
|
| 0.001 | 0.001 | ||||
| Medicare, private insurance, charity | 1.00 (ref) | 1.00 (ref) | ||||
| Self-pay | 1.75 | 1.25–2.47 | 0.005 | 1.64 | 1.15–2.32 | 0.006 |
| Medicaid | 1.62 | 1.15–2.28 | 0.001 | 1.74 | 1.21–2.49 | 0.003 |
|
| 0.001 | 0.001 | ||||
| Bone/joint, skin/soft tissue, intra-abdominal, genitourinary | 1.00 (ref) | 1.00 (ref) | ||||
| Bacteremia | 1.43 | 1.03–1.99 | 0.05 | 1.43 | 1.03–1.99 | 0.03 |
| Central nervous system | 0.32 | 0.10–0.99 | 0.04 | 0.31 | 0.10–0.97 | 0.04 |
| Pulmonary/ENT | 0.43 | 0.19–0.98 | 0.05 | 0.44 | 0.19–1.02 | 0.06 |
| Other type/site | 0.55 | 0.30–0.99 | 0.003 | 0.54 | 0.29–0.98 | 0.04 |
|
| 0.003 | 0.003 | ||||
| No | 1.00 (ref) | 1.00 (ref) | ||||
| Yes | 1.72 | 1.21–2.46 | 0.003 | 1.74 | 1.21–2.51 | 0.003 |
|
| 0.12 | |||||
| 1 | 1.00 (ref) | |||||
| 2 | 1.55 | 0.40–1.05 | 0.08 | |||
| 3 | 1.09 | 0.53–1.57 | 0.75 | |||
| 4 | 1.28 | 0.44–1.39 | 0.40 | |||
| 5 | 0.89 | 0.60–2.08 | 0.72 | |||
Model 1 controls for confounding with covariates; model 2 controls for confounding with covariates and for selection bias with the propensity score.
*The p-values for the main category terms are the effects from the type 3 tests, and those for the individual category terms are the maximum likelihood estimates, all based on a sample size of 1,168.
‡Replication of the two models with multiple logistic regression analysis gave similar results for all estimates; specifically, the odds ratio for S-OPAT was 0.59 (95% CI 0.40–0.86) in model 1 and 0.55 (95% CI 0.34–0.89) in model 2.
†Reanalysis after excluding patients in quintiles 4 and 5 of the categorical propensity score gave an aHR for S-OPAT of 0.51 (95% CI 0.33–0.79; p = 0.003). When the continuous propensity score was used in the model as a quadratic effect, the aHR for S-OPAT was 0.52 (95% CI 0.34–0.80; p = 0.003).
ENT, ear/nose/throat; ref, referent category.
Multivariable proportional hazards regression models of 1-y mortality.
| Variable | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| aHR | 95% CI |
| aHR | 95% CI |
| |
|
| 0.73 | |||||
| H-OPAT | 1.00 (ref) | 1.00 (ref) | ||||
| S- OPAT | 0.94 | 0.45–1.96 | 0.87 | 0.86 | 0.37–2.00 | |
|
| <0.001 | |||||
| Medicare, Medicaid, private, charity | 1.00 (ref) | 1.00 (ref) | ||||
| Self-pay | 4.23 | 2.47–7.23 | <0.001 | 5.48 | 3.09–9.73 | |
|
| 0.01 | |||||
| White, black, other | 1.00 (ref) | 1.00 (ref) | ||||
| Hispanic | 1.69 | 1.00–2.85 | 0.05 | 1.94 | 1.14–3.31 | |
|
| 0.01 | |||||
| No | 1.00 (ref) | 1.00 (ref) | ||||
| Yes | 0.06 | 0.01–0.46 | 0.006 | 0.08 | 0.01–0.60 | |
|
| 0.002 | |||||
| <65 y | 1.00 (ref) | 1.00 (ref) | ||||
| ≥65 y | 2.71 | 1.56–4.71 | <0.001 | 2.48 | 1.41–4.37 | |
|
| 0.008 | |||||
| 1 | 1.00 (ref) | |||||
| 2 | 2.47 | 0.15–1.08 | 0.07 | |||
| 3 | 1.31 | 0.26–2.28 | 0.63 | |||
| 4 | 1.20 | 0.27–2.58 | 0.75 | |||
| 5 | 0.44 | 0.59–8.70 | 0.24 | |||
Model 1 controls for confounding with covariates; model 2 controls and for confounding with covariates and for selection bias with the propensity score.
*The p-values for the main category terms are the effects from the type 3 tests, and those for the individual category terms are the maximum likelihood estimates, all based on a sample size of 1,168.
‡Replication of the two models with multiple logistic regression analysis gave similar results for all estimates; specifically, the odds ratio for S-OPAT was 1.09 (95% CI 0.50–2.39) for model 1 and 1.05 (95% CI 0.43–2.55) for model 2.
†Reanalysis after excluding patients in quintiles 4 and 5 of the propensity score gave an aHR for S-OPAT of 0.82 (95% CI 0.35–1.91; p = 0.64). When the continuous propensity score was used in the model as a quadratic effect, the aHR for S-OPAT was 0.91 (95% CI 0.40–2.03; p = 0.81).
ref, referent category.
Impact of the self-administered OPAT program on the hospital’s inpatient bed utilization.
| Fiscal Year of Index Hospital Discharge | Number of S-OPAT Patients | Median Number of Days of Outpatient Therapy per Patient | Total Number of Days of Outpatient Therapy for All S-OPAT Patients | Average Number of Inpatient Hospital Beds Avoided per Day |
|---|---|---|---|---|
| 2010 | 104 | 17 | 2,211 | 6.1 |
| 2011 | 231 | 27 | 6,848 | 18.7 |
| 2012 | 305 | 27 | 9,112 | 24.9 |
| 2013 | 304 | 29 | 9,495 | 26.0 |
| All years | 944 | 26 | 27,666 |
*Before the S-OPAT clinic was started, all of these days would have been spent in the hospital just to receive antimicrobial infusions.